



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Graham Charles Bloomfield et al.

Serial No:

10/568,053

Group Art Unit:

Filed:

June 18, 2008

Examiner:

For:

5-PHENYL-4-METHYL-THIAZOL-2-YI-AMINE DERIVATIVES OF

PHOSPHATIDYLIN OSITOL 3 KINASE ENZYMES (PI13) FOR

TREATMENT OF INFLAMMATORY DISEASE

## RESPONSE TO RESTRICTION REQUIREMENT

**Commissioner for Patents** P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the Restriction Requirement set forth in the Office Action dated November 10, 2008, Applicants hereby elect, with traverse, Group 1 (Claims 14-20) and elect Example 110 in Table 7 of the specification as the invention to be examined. Applicants expressly reserve the right to file divisional applications or other appropriate measures deemed necessary to protect the inventions in the remaining, unelected claims.

The Commissioner is hereby authorized to charge any fees in connection with this Response to Deposit Account No. 50-4409.

By:

April 3, 2009

Vinit Kathardekar

Attorney for Applicants

Respectfully submitted,

Reg. No. 39,461

NOVARTIS VACCINES AND DIAGNOSTICS, INC.

Intellectual Property – X-100B

P.O. Box 8097

Emeryville, California 94662-8097

(510) 923-3949

(510) 655-3542 (fax)

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class mail in an envelope addressed to: Mail Stop

Commissioner for Patents, P.O. Box 1450,

Alexandria, VA 22313-1450, ()